Ketamine Therapy in Pennsylvania: A 2026 Guide

Pennsylvania has one of the largest and most established healthcare systems in the United States, and ketamine therapy has grown into a recognizable option within that ecosystem. Clinics are concentrated in Philadelphia, Pittsburgh, and the suburban counties around them, but providers exist in mid-state markets like Harrisburg and Allentown as well.

This guide covers the regulatory landscape in Pennsylvania, what to expect from insurance coverage under PA MA and major commercial payers, and how to evaluate a provider. It is educational information only — your licensed clinician should guide any treatment decisions.

Ketamine Therapy: The Basics

Ketamine has been used as an anesthetic in hospitals for decades. At sub-anesthetic doses, many clinicians use it off-label for treatment-resistant depression (ICD-10: F32.9, F33.2), certain anxiety disorders (F41.1), PTSD, and chronic pain.

IV ketamine infusions are administered in a clinical setting, typically as a series of six infusions over two to three weeks. Because this is an off-label use, the drug itself is billed as a miscellaneous injection (CPT J3490), alongside appropriate evaluation and management codes (99213 or 99214).

Spravato (esketamine nasal spray) was FDA-approved in 2019 for treatment-resistant depression and major depressive disorder with suicidal ideation. It is administered in a certified healthcare setting with at least two hours of post-dose monitoring. The FDA maintains approval information at FDA.gov. Spravato’s defined FDA indication matters for insurance purposes in Pennsylvania, as explained below.

Who Oversees Ketamine Providers in Pennsylvania?

Pennsylvania physicians who administer ketamine must hold an active license from the Pennsylvania State Board of Medicine, which operates under the Pennsylvania Department of State’s Bureau of Professional and Occupational Affairs. License verification is available through the Department of State’s online portal at dos.pa.gov.

Osteopathic physicians are licensed separately by the Pennsylvania State Board of Osteopathic Medicine. Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) who work in ketamine clinics practice under collaborative agreement requirements as defined by their respective Pennsylvania licensing boards.

Spravato clinics must comply with the FDA’s REMS program, which certifies dispensing sites and requires that patients be monitored on-site after each dose by a certified healthcare professional.

You can confirm any provider’s national credential by looking up their NPI number through the NPPES NPI Registry.

Pennsylvania Insurance Coverage: PA MA and Commercial Plans

Coverage is complex in Pennsylvania, but the landscape has improved for Spravato since its FDA approval.

Pennsylvania Medical Assistance (PA MA), the state’s Medicaid program, covers Spravato for qualifying members who meet clinical criteria — generally, documentation that two or more adequate antidepressant trials have failed. Prior authorization is required. PA MA managed care organizations (MCOs), including Highmark Wholecare, UPMC for You, and others, administer these benefits, and policies can vary by MCO. Contact your specific plan to understand its prior authorization requirements.

Off-label IV ketamine infusions are generally not covered by PA MA as of 2026.

Commercial insurers in Pennsylvania have varied approaches. Highmark Blue Cross Blue Shield of Pennsylvania and Independence Blue Cross (dominant in the Philadelphia region) both offer Spravato coverage on many plans, subject to prior authorization and step therapy requirements. UnitedHealthcare and Aetna plans sold in Pennsylvania follow similar patterns. IV ketamine infusions remain largely out-of-pocket expenses for commercially insured patients, though associated evaluation visits may be billable under standard psychiatric or primary care codes.

Some Pennsylvania ketamine clinics employ benefits coordinators who can help you navigate the prior authorization process. It is worth asking whether a clinic offers this support before you commit.

Finding a Licensed Provider in Pennsylvania

Pennsylvania’s geography means provider access varies significantly. Philadelphia-area patients have many options; patients in rural central or northern Pennsylvania may need to travel or consider telehealth for initial evaluations (subject to Pennsylvania’s prescribing regulations).

When evaluating a Pennsylvania ketamine provider, ask:

Is the administering clinician licensed by the Pennsylvania State Board of Medicine or Pennsylvania State Board of Osteopathic Medicine?
Does the clinic conduct a psychiatric evaluation (CPT 90791) before starting treatment?
What is the monitoring protocol during and after infusions?
Does the clinic communicate with your existing psychiatrist or therapist?
What follow-up care is offered after the initial series?

What the Treatment Process Looks Like

Most Pennsylvania ketamine clinics begin with an intake evaluation — either psychiatric or medical — to assess your history, current medications, and treatment goals. You should receive written informed consent documentation before any treatment begins.

IV infusions typically run 40 to 60 minutes. Most patients experience some degree of dissociation during the infusion. You will need a driver; do not plan to drive yourself home after treatment.

Spravato sessions are self-administered under clinical supervision in the clinic, with the required two-hour monitoring period afterward.

Responses to ketamine therapy vary considerably. Some patients report meaningful improvement during or after the initial series; others require a longer course or maintenance sessions. Ketamine is generally considered a complement to ongoing psychiatric care, not a standalone solution.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.